Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment
Launched by IRCCS POLICLINICO S. DONATO · Jan 18, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how Marfan syndrome (MFS) affects the shape and features of the face. Researchers want to understand specific facial characteristics associated with MFS and how these features might change over time. They are also looking to see how these facial traits relate to the main signs used to diagnose MFS. This study is important because it could help improve the way doctors identify and understand Marfan syndrome.
Anyone interested in participating must be of White European descent and able to give their consent to join the study. However, people who have had significant facial injuries or surgeries, those who are pregnant, or those with facial hair like beards or mustaches are not eligible. Participants will undergo non-invasive 3D assessments, which means they will have their facial features scanned without any discomfort. This is a great opportunity to contribute to valuable research that may help others with Marfan syndrome in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • White european ethnicity;
- • Signed informed consent;
- Exclusion Criteria:
- • Previous relevant traumas affecting the craniofacial district or maxillofacial surgery;
- • Presence of beard and mustache;
- • Pregnancy
About Irccs Policlinico S. Donato
IRCCS Policlinico S. Donato is a leading Italian research hospital and clinical trial sponsor dedicated to advancing medical science through innovative research and patient care. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it is recognized for its commitment to high-quality clinical research and the integration of scientific investigation with clinical practice. The institution specializes in various medical fields, including cardiology, oncology, and neurology, and collaborates with universities and research organizations to facilitate cutting-edge studies. With a focus on improving patient outcomes and contributing to public health, IRCCS Policlinico S. Donato plays a pivotal role in the development of new therapies and treatment protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Donato Milanese, Milan, Italy
San Donato Milanese, Lombardia, Italy
Patients applied
Trial Officials
Alessandro Pini, MD
Principal Investigator
Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials